24/7 Market News Snapshot 14 August, 2025 – BioSig Technologies, Inc. Common Stock (NASDAQ:BSGM)
DENVER, Colo., 14 August, 2025 (www.247marketnews.com) – (NASDAQ:BSGM) are discussed in this article.
BioSig Technologies, Inc. (BSGM) is currently experiencing a significant upward trend in trading, opening at $4.52 and surging to approximately $5.095, reflecting a notable increase of around 10.76%. This is in contrast to its previous close of $4.60. The trading volume has reached 1.61 million shares, indicating heightened investor interest and enhanced liquidity. Analysis of the price movement shows the stock has successfully breached key resistance levels, suggesting potential for continued upward momentum. Investors are advised to monitor support levels around $4.60 and resistance at $5.20 as they strategize for future trades.
In alignment with its financial strategy, BioSig has also announced the pricing of its underwritten public offering, following its merger with Streamex Exchange Corporation. The offering comprises 3,852,149 shares of common stock priced at $3.90 each, anticipating gross proceeds of approximately $15 million, before deducting underwriter discounts and expenses. This strategic capital infusion is designed to bolster BioSig’s financial framework and support its growth within the dynamic medical technology sector.
The offering’s closing is expected around August 15, 2025, pending customary closing conditions. The net proceeds are earmarked for purchasing gold bullion, in accordance with the Company’s investment strategy, and for general corporate purposes. Clear Street and Needham & Company have been designated as joint book-running managers for this offering, which operates under a shelf registration statement that was deemed effective by the Securities and Exchange Commission (SEC) on December 17, 2024.
BioSig Technologies remains focused on advancing cardiac medical technology through its innovative PURE EP™ platform. This platform provides critical insights that enhance electrophysiologists’ efficacy in treating cardiovascular arrhythmias, thereby improving patient outcomes and procedural efficiency. With these significant developments, BioSig is positioned for future growth and a stronger market presence in the evolving healthcare landscape.